A proof-of-concept study of a a third generation antisence platform, NLRP3 (NOD-like receptor family, pyrin domain containing protein 3) and DUX4 (Double Homeobox 4)

Trial Profile

A proof-of-concept study of a a third generation antisence platform, NLRP3 (NOD-like receptor family, pyrin domain containing protein 3) and DUX4 (Double Homeobox 4)

Planning
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs Antisense oligonucleotides (Primary) ; Oligonucleotides (Primary)
  • Indications Facioscapulohumeral muscular dystrophy; Interstitial cystitis; Lupus nephritis; Uveitis
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 17 Aug 2016 New trial record
    • 02 Aug 2016 According to an Idera Pharmaceuticals media release this study is expected to initiate in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top